Skip to main content

Table 3 Laboratory findings in a trial of HDIVC in patients with COVID-19

From: Pilot trial of high-dose vitamin C in critically ill COVID-19 patients

Variable

Day

Vitamin C (n = 27)

Placebo (n = 29)

Difference, coefficient (95% CI)

P Value

Leukocyte count, 109

1

9.5 ± 5.0

11.6 ± 7.2

− 2.0(− 5.4 to -1.5)

0.26

3

8.6[5.7–11.5]

8.4[7.1–12.2]

− 0.4(− 3.5 to 2.7)

0.67

7

10.2 ± 6.7

9.6 ± 5.4

0.6(− 3.0 to 4.1)

0.74

Neutrophil count, 109

1

8.2 ± 4.8

10.2 ± 7.1

− 2.0(− 5.3 to 1.4)

0.24

3

6.2[4.5–10.5]

7.1[5.7–9.9]

− 0.5(− 3.5 to 2.5)

0.50

7

8.1 ± 6.5

8.2 ± 5.5

− 0.1(− 3.6 to 3.4)

0.95

Neutrophil ratio, %

1

83.5 ± 9.6

85.8 ± 9.9

− 2.3(− 7.7 to -3.1)

0.39

3

85.7[77.1–91.4]

83.3[75.5–91.8]

4.0(− 6.3 to 14.4)

0.70

7

78.5 ± 15.8

81.7 ± 11.5

− 3.2(− 11.2 to 4.8)

0.42

IL-6

1

22.6[8.9–85.5]

54.7[12.3–145.5]

-6.2(-129.7 to 117.3)

0.61

3

113.1[21.8–288.7]

37.2[5.6–85.3]

92.4(− 25.1 to 210.0)

0.07

7

19.4[10.6–29.2]

158.0[15.3–259.6]

− 165.8(− 301.7 to − 29.8)

0.04

Lymphocyte count, 109

1

0.6[0.4–1.0]

0.5[0.4–1.0]

0.1(− 0.2 to 0.4)

0.49

3

0.6[0.3–1.0]

0.71[0.5–1.1]

− 2.6(− 8.6 to 3.4)

0.50

7

0.8[0.4–1.1]

0.7[0.4–1.0]

1.1(− 0.8 to 3.0)

0.25

Lymphocyte ratio, %

1

9.7 ± 7.0

8.1 ± 7.3

1.6(− 2.3 to 5.6)

0.41

3

10.1 ± 9.2

8.7 ± 4.9

1.4(− 2.7 to 5.4)

0.88

7

13.1 ± 11.3

6.8[5.1–13.4]

3.3(− 2.1 to 8.8)

0.23

PCT, ng/mL

1

0.2[0.1–0.6]

0.2[0.1–0.5]

− 9.9(− 29.3 to 9.4)

0.80

3

0.4[0.1–3.2]

0.3[0.1–1.1]

− 6.6(− 20.5 to 7.3)

0.84

7

0.3[0.1–14.8]

0.2[0.1–0.7]

13.3(− 17.9 to 44.5)

0.18

CRP, mg/L

1

39.9[3.9–86.9]

56.8[40.2–100.2]

− 23.2(− 69.5 to 23.1)

0.19

3

43.5[3.4- 65.7]

66.3[29.8–107.4]

− 4.8(− 68.1 to 58.5)

0.28

7

29.5[11.0–110.9]

30.2[2.3–131.7]

− 12.6(− 75.3, 50.1)

0.68

Total bilirubin, umol/L

1

8.6[6.8- 15.6]

10.8[7.4–18.3]

− 1.5(− 7.3 to 4.4)

0.28

3

8.4[6.7–16.1]

14.9[9.9–25.5]

− 9.7(− 18.3 to − 0.6)

0.03

7

8.3[6.5–16.2]

15.3[9.0–27.7]

− 4.2(− 15.9 to 7.5)

0.11

Creatinine, umol/L

1

64.2[46.9–85.5]

64.2[52.0 -81.7]

26.4(− 50.9 to 103.7)

0.57

3

60.3[37.7–80.4]

70.35[49.80–100.9]

2.5(− 39.9 to − 44.9)

0.15

7

57.5[40.0–7]

63.50[51.7–104.5]

− 12.4(− 45.6 to 20.7)

0.13

BUN, mmol/L

1

7.11[4.48–11.10]

6.50[4.9–9.9]

9.3(− 8.8 to 27.4)

0.84

3

7.6 ± 5.0

8.6[5.1–11.4]

− 2.1(-5.2 to − 1.0)

0.11

7

8.5 ± 5.7

7.8[5.1–10.5]

− 0.7(− 4.1 to 2.7)

0.48

PT, s

1

13.3[12.4–14.6]

12.9[12.5–13.8]

− 0.6(− 2.4 to 1.2)

0.97

3

13.9 ± 3.2

13.3[12.7–15.1]

− 0.29(− 2.0 to 1.4)

0.33

7

13.0 ± 2.6

13.1[12.4–14.6]

− 0.3(− 1.7 to 1.1)

0.08

  1. Data were expressed as mean ± standard deviation, as median [interquartile range]. Odds ratio with 95% CI were calculated by binary logistic regression for the rest. P values were calculated by logistic regression
  2. SD standard deviation, IQR interquartile range, HR hazard ratio, OR odds ratio, CI confidence interval, HDIVC high-dose intravenous vitamin C, COVID-19 coronavirus disease 2019, SD standard deviation; IQR interquartile range, PCT procalcitonin, CRP C-reactive protein, BUN blood urea nitrogen, PT prothrombin time, IL-6 interleukin-6